EASME

Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.

Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, specializing in the development of a metabolism-based liquid biopsy platform aimed at the early detection and monitoring of cancer. Founded in 2017, the company focuses on measuring biomarkers in blood and urine, employing machine learning and artificial intelligence algorithms to identify cancer signatures. Elypta is actively conducting the AURORAX clinical trial series to explore applications for its platform, particularly in renal cell carcinoma, while also investigating other cancer indications. The technology includes a new in vitro diagnostic laboratory assay kit, which enables comprehensive profiling of glycosaminoglycan metabolites and supports a range of applications from screening to treatment response monitoring, facilitating earlier interventions in cancer care.

Cardioset Medical is a group of scientists and business people who strive to make a life-changing impact on patients suffering from heart failure lung edema. With over 15 years of research and development we now have the solution that can literally revolutionize millions of HF patients' lives by enabling them to self-monitor their lung edema state and detect small changes at an even earliest stage.

CLOVER Bioanalytical Software is a bioinformatics company specialized in data processing for Bioanalytical Chemistry and Microbial ID and other clinical diagnostics applications using mass spectrometry. Formed by a group of Ph.D. graduates with a wide expertise in business and research, it brings a perfect match to develop cutting-edge software and statistical analysis projects in the biomedical field. They are specialized in mass spectrometry, its clinical applications and mass spectrometry imaging. But their expertise cover many more applications, like medical image processing, univariate and multivariate statistical analysis, and Big Data. They are truly customer-oriented, keeping in mind the goals of their clients and the scalability of the systems. They count with experts in biomedicine, chemistry and biotechnology that speak your own language and understands your needs.

Limbic is a London-based company that specializes in mental healthcare technology. Founded in 2017, it develops a software development kit (SDK) that leverages machine learning to analyze heart rate data collected from wearable devices like the Apple Watch, allowing for the assessment of users' emotional states. Limbic also offers psychological therapies for adults, focusing on improving mental health through innovative solutions. Its platform supports healthcare professionals by providing tools for stress detection and facilitating clinical assessments, thereby enhancing the efficacy of psychological therapy. By combining AI technology with wearable devices, Limbic aims to address the growing challenges in mental health care and improve patient outcomes.

Delta Diagnostics, founded in 2018 as a spin-off from TNO – The Netherlands Organisation for Applied Scientific Research, specializes in photonic biosensor technology. The company leverages patented innovations developed in TNO's Optics department to commercialize rapid, sensitive, and low-cost biosensors and instruments. These advanced biosensors utilize integrated photonics and optical chips containing waveguides that facilitate the transportation of light across multiple sensors. This technology enables real-time, label-free monitoring of biomarkers, allowing for accurate concentration measurements within minutes. Delta Diagnostics aims to enhance research in life sciences and facilitate the development of novel diagnostics through its innovative biosensing solutions.

CMI NOV is a healthcare company provides solution for mitral valve repair during open heart surgery.

Nateo Healthcare, founded in 2016 and based in Toulouse, France, specializes in designing, developing, and manufacturing medical devices for the fields of gynecology and obstetrics. The company focuses on creating innovative connected medical devices and software that enable healthcare professionals to monitor the health of expectant mothers and their unborn babies. Among its key products is a belt equipped with ultrasound probes that can assess fetal positions, measure the mother's heart rate, and monitor uterine contractions. Additionally, Nateo Healthcare is working on a new generation of mobile and connected fetal heart rate monitors, which facilitate both hospital and home fetal telemonitoring, allowing for enhanced patient self-monitoring and tailored healthcare interventions.

Hedia is a health application designed to assist individuals with type 1 and type 2 diabetes by leveraging artificial intelligence. The application analyzes the user's patterns and habits, providing personalized insulin recommendations based on their carbohydrate intake and exercise levels. By facilitating better insulin management, Hedia aims to enhance the everyday lives of people living with diabetes, making it easier for them to control and monitor their condition effectively.

CreatSens develops a platform that provides paper-based creatinine and potassium potentiometric sensors solutions to the healthcare industry. It helps healthcare professionals to better manage the information that can be generated in primary care centers, doctor’s office or patient’s homes. CreatSens platform aims to improve the well-being of people by allowing the monitoring of relevant biochemical parameters of blood out of the lab. The biochemical and physical information will be integrated into a technological platform allowing an accurate prediction, early detection and better prevention of acute conditions from home. The company was founded in 2017 and is headquartered in Tarragona, Catalonia, Spain.

Stokhos started as a scientific mathematical project named REPRO with the aim to reduce ambulance response times. The potential social impact motivated the foundation of Stokhos. We at Stokhos are all very enthusiastic about mathematics and science and are tirelessly working on making the world a safer place. As their products were first developed for he medical emergency market, we have a strong affinity with the medical emergency field. All members of their team, do, for example, have valid first aid certification.

Vibrosonic GmbH is a company specializing in the development, production, and marketing of innovative hearing solutions tailored for individuals with varying degrees of hearing impairment. Originating as a spin-off from the Fraunhofer Project Group for Automation in Medicine and Biotechnology and the University ENT Clinic Tübingen, Vibrosonic focuses on creating discreet hearing devices that integrate advanced microsystem technologies. Their unique approach involves the use of piezoelectric principles to design hearing contact lenses that can be directly placed on the eardrum. This technology transmits sound through vibrations rather than traditional speakers, enhancing the auditory experience while minimizing discomfort for users. Through its specialized equipment, Vibrosonic aims to improve the quality of life for those affected by hearing loss.

Segmentum Imaging is a brand new app allowing you to count samples more quickly than traditional methods have previously allowed, whilst releasing you from the confines of the lab. Do your work conveniently, increasing your output and decreasing your time spent on repetitive actions. The adoption of digital pathology has been increasing dramatically. It is being used for more convenient diagnosis, easier sharing of images between consultants, large-scale collection for research purposes and in the creation of online virtual archives, critical in teaching and multi-centre research. Whilst the tools for researchers to utilise digital images have become very advanced, they are often very expensive and are commonly based in individual laboratories. This can easily result in considerable bottlenecks in use and limitations of access often lead to these facilities being simultaneously very costly but under-utilised.

Probiomedica combines engineering, biology, photonics and robotics, and aims to develop innovative devices for the application to health and personal care.

ControlNano is a spin-off company leaded by a group of professionals with high expertise in the field of health risk assessment related to the exposure of nanoparticles in industrial facilities and urban environments. They design and manufacture highly reliable and robust devices to provide accurate information on the concentration levels of nanoparticles and respirable dust in air.

Taliaz is revolutionizing the treatment and management of mental health disorders with PREDICTIX. PREDICTIX is a CE registered product that provides an advanced decision support software for psychiatrists and general practitioners. Harnessing artificial intelligence (AI), PREDICTIX can enable easy, effective and rapid patient assessment, improved prescribing precision and management for a wide range of mental health conditions. PREDICTIX understands that mental health disorders are multifaceted and unique. Combining data science with machine learning, PREDICTIX translates complex genetic, metabolic, demographic and clinical data into an easy-to-use assessment and prescribing support tool. Starting in the field of depression where the right antidepressant is only prescribed in 49% of cases (Chekroud et al., 2016), PREDICTIX improves treatment prescribing accuracy by 47% to achieve 72% prescribing accuracy*. PREDICTIX PRODUCTS - PREDICTIX Digital – 30% improvement in prescribing accuracy*. Combines AI analysis of patients’ clinical and demographic data to support doctor prescribing decisions. - PREDICTIX Genetics – 47% improvement in prescribing accuracy*. Further optimizes treatment decisions by combining a patient’s DNA analysis with AI. PREDICTIX is an ideal software solution for payors, providers, DNA laboratories and telemedicine providers to improve patient outcomes, reduce costs and expand service offerings in the mental health space. PREDICTIX is commercially available in Europe. Learn more at predictix.ai. *Based on a retrospective analysis of four STAR*D study medications. STAR*D is one of the world’s largest prospective studies for optimal antidepressant administration. Disclaimer: Taliaz is developing the PREDICTIX Genetics and PREDICTIX Digital products. PREDICTIX (Genetics) Antidepressant is currently available for commercial use in the EU and Israel. Outside of the EU and Israel, PREDICTIX Genetics products are currently limited by law for investigational use only. PREDICTIX Digital products are currently limited by law for investigational use only.

BioMensio Ltd. is a biotechnology company based in Tampere, Finland, established in 2015. It specializes in developing smart multi-analyte handheld detection devices for bio-analytics, providing rapid and on-site detection of various biological targets from a small sample in a single step. The company's offerings include a novel miniaturized micro-array platform that supports the quick development of new bio-screening applications, which are applicable in areas such as saliva testing, food and milk safety, point-of-care diagnostics, and bio-security. BioMensio's technology enables the creation of label-free assays, allowing for the detection of multiple analytes without the need for labeling procedures. Additionally, its Diagnostics-as-a-Service (DXaaS) platform integrates a handheld reader, multianalyte fluid cartridges, and cloud-based analytics, facilitating easier access for original equipment manufacturers (OEM) to develop bio-analysis products and services.

CardiacSense is an innovative start-up on track to revolutionize the Wearable Health Industry by providing affordable, comfortable FDA & CE certified Medical Watches and Wristbands capable of continuous, long term, ambulatory and non-invasive monitoring of life critical functions including Heart Rate, Pulse Rate, Respiratory Rate, Core Temperature, Oxygen Saturation and Blood Pressure. These capabilities enable accurate real time diagnostics of medical conditions such as Heart Arrhythmias (incl. Atrial Fibrillation), Hypertension, COPD, Heart Failure, Sleep Apnea and infections (such as COVID-19).

SensoGenic, Inc. develops innovative diagnostic biosensors specifically designed to detect food allergens. Founded in 2016 and based in Ness Ziona, Israel, the company offers portable, handheld analyzers that connect to a mobile application, allowing users to identify allergens without physical contact. This technology provides critical information for individuals with food allergies, enabling them to dine out safely and avoid allergic reactions. SensoGenic emphasizes understanding user needs to enhance the functionality and usability of its products, positioning itself as a leader in allergen detection solutions.

eLive Ecosystem provides next generation solution for preventing longterm diseases and their disadvantages.

Picterus is developing a smartphone application aimed at diagnosing jaundice in newborns, a condition that contributes to over 100,000 deaths annually, particularly in impoverished areas of Sub-Saharan Africa and South Asia. Existing screening devices are prohibitively expensive, often costing around $7,000, which limits access in low-resource settings. The app utilizes patented biomedical optics technology to provide accurate estimates of jaundice levels while accounting for variations in skin pigmentation. This innovation addresses the growing need for affordable and effective diagnostic tools, especially given the trend of shorter hospital stays post-birth and the rising rates of jaundice-related hospital readmissions. By enabling parents to monitor their child's jaundice levels at home, Picterus aims to improve health outcomes for vulnerable populations.

MyoSwiss AG, founded in 2017 and based in Zurich, Switzerland, specializes in medical technology aimed at enhancing mobility for individuals with muscle weakness. The company develops innovative products such as the Myofit and Myosuit, which serve as advanced training devices for rehabilitation and physiotherapy. These devices are designed to improve the quality of life for users by providing an additional layer of muscle support, thereby enabling them to regain their mobility and independence. MyoSwiss also offers personalized training plans, intensive activity-based training, and performance tracking to enhance the effectiveness of its solutions, helping individuals with mobility impairments realize their potential for physical activity.

ODI Medical specializes in developing innovative technology for the bedside evaluation of circulatory failure through the assessment of microcirculation. The company's medical device streamlines the collection of microvascular data and has diverse clinical applications. These include monitoring patients on mechanical heart and lung machines, evaluating the toxicity of chemotherapy, and early detection of evolving sepsis. Additionally, the technology is useful for monitoring chronic wounds and conducting mass screenings for conditions such as Ebola, bird flu, and epidemic meningitis. By employing non-invasive techniques, ODI Medical enables healthcare professionals to enhance patient therapy through improved assessment of microcirculation.

Medfield Diagnostics AB, founded in 2005 by Mikael Persson and Andreas Fhager, specializes in the development and commercialization of diagnostic instruments utilizing microwave technology. The company focuses on advancing stroke diagnostics through its innovative products, including Strokefinder and Impending Applications. By leveraging promising research conducted at Chalmers University of Technology, Medfield Diagnostics aims to enhance the accuracy and efficiency of stroke detection and management.

Mecwins specializes in developing advanced nanomechanical sensing technology to create sensitive immunoassays aimed at improving healthcare outcomes for individuals at risk for oncology, cardiovascular diseases, and infectious diseases. Their innovative platform combines nanomechanical sensing with plasmonic emission using a sandwich immunoassay approach, allowing for the production of ultrasensitive detection systems. This technology enables researchers to achieve enhanced sensitivity in disease detection, ultimately contributing to better diagnostics and treatment options in critical areas of healthcare.

TomoWave commercializes and produces innovative imaging modalities with applications in clinical medicine and preclinical research. Our proprietary technology “listens to the sound of light” to produce highly resolved images from the depth of tissues. The main targeted medical needs of TomoWave platform technology include detection and diagnostics of cancer, image guided interventions and monitoring the effectiveness of anticancer therapy and diagnostics imaging of vascular and blood related conditions. A pipeline of innovative optoacoustic and laser ultrasonic imaging technologies based on inventions made by the company founder, Dr. Alexander Oraevsky, pioneer of biomedical optoacoustics and recipient of multiple grants and awards for development of molecular imaging systems and applications. TomoWave Laboratories has the capability to generate intellectual property and develop its IP from idea to validated clinical prototypes and brings these technologies to the market place through regulatory certification.

Pre Diagnostics is an innovative Norwegian diagnostic company that seeks to create value for patients, partners, and investors by developing pioneering and patient-friendly, in-vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept is built upon the scientific premise that a disease evokes systemic responses in macrophages unique to that disease which can be accurately measured in the blood samples of patients. Pre Diagnostics aims to be a leader in the diagnosis of early Alzheimer’s disease and is thus focused on the development of IVD biomarker products that use well-established technologies and procedures.

The WLTS laboratory is organized to take samples of asbestos (air and material) and to analyze the samples taken.

Enzymlogic specializes in enzymology and protein science, offering analytical services aimed at enhancing drug discovery and development for the pharmaceutical and biotech industries. The company assists in identifying kinetic profiles during the drug development process, which helps clinicians understand the interactions between drugs and their targets. This insight is crucial for evaluating factors that influence efficacy and safety, ultimately contributing to the creation of innovative therapies that improve patients' quality of life. Enzymlogic aims to become a key resource for organizations focused on successful drug discovery, ensuring their clients achieve optimal returns on investment while advancing therapeutic solutions.

Capitainer AB, based in Stockholm, Sweden, specializes in manufacturing innovative blood collection devices for micro sampling, allowing patients to collect their own volume-defined dried blood spots at home. Founded in 2016, Capitainer's technology offers a more accurate and convenient alternative to traditional blood sampling methods, significantly reducing the need for patients to travel for tests. By facilitating remote blood sample collection that can be sent to laboratories through regular mail, Capitainer enhances the efficiency of healthcare providers and contributes to cost and environmental savings associated with managing conventional blood samples.

Dytective is the scientifically validated reference tool for detection and improvement of skills related to dyslexia. Dytective combines two scientifically validated tools developed by Change Dyslexia. In only 15 minutes, through a series of tests, according to your age and abilities, Dytective Test detects if you are at risk of having dyslexia. With DytectiveU you will improve your reading and writing skills while having fun playing.

BIOsens Inc. specializes in developing biosensors for the rapid quantitative diagnostics of food toxins, particularly mycotoxins. The company offers a testing device that allows for easy sample preparation and delivers results within 15 minutes. These results are stored in the cloud, utilizing Internet of Things (IoT) technology. By providing efficient and reliable testing solutions, BIOsens aims to enhance food safety and help consumers trust the safety of their food products.

CRU network has been providing clinical research services to the pharmaceutical industry for over a decade and basic/academic research services since 2015. In the recent years next to the research activities many new healthcare services were initiated within the EU and in South-East Asia. CRU sites are located in Hungary, Ukraine, Germany, Vietnam and LAO PDR.

PlanDomino specializes in digital lab scheduling software designed to enhance the efficiency of resource allocation and manage testing workflows in laboratories. By utilizing a fully digitized system, PlanDomino enables significant productivity improvements, with potential savings exceeding 50 percent, while reducing lead times and eliminating the need for extensive training or costly consultants. The platform incorporates visual management technology to connect laboratory operations with supply chains, fostering collaboration among different departments. This integrated approach enhances the allocation of work for analysts and provides comprehensive visibility of samples as they progress through the lab, ultimately streamlining processes and boosting overall productivity.

Bambi Medical is a MedTech company founded in November 2015 by Sidarto and Fabio Bambang Oetomo, aiming to alleviate pain and stress in pre-term infants while enhancing parent-child bonding. The company specializes in the design, development, and manufacturing of innovative products for Neonatal Intensive Care Units (NICUs) in hospitals. One of its key offerings is a wireless health monitoring device that tracks critical health metrics such as breathing, heart rate, temperature, and electrocardiogram (ECG) without the discomfort associated with traditional adhesive electrodes. This device facilitates maximum skin-to-skin contact between infants and their parents, allowing for effective monitoring of the baby's health while minimizing pain and skin irritation.

Preventicus GmbH, founded in 2014 and headquartered in Jena, Germany, develops innovative health solutions that utilize smartphone and smartwatch technologies to monitor vital parameters. The company's main product, Preventicus Heartbeats, is a class I medical device designed to identify atrial fibrillation, a condition that increases the risk of stroke. This smart screening solution allows users to check their heart rhythm quickly and conveniently, requiring no additional accessories. The software applications are certified medical devices and have demonstrated a level of accuracy previously achievable only by physicians, making them valuable for private users, corporate clients in occupational health management, and OEM customers. Preventicus focuses on early preclinical risk screening for lifestyle-related illnesses, including heart attacks and strokes, effectively enhancing personal health management.

Arrhythmia Algorithm S.L. (https://rithmi.com) is a privately held company with the mission to support people to take care of their heart and prevent health problems as the stroke. Their aim is to revolutionize the way Auricular fibrillation is diagnosed through a comfortable, compliant and innovative method. After successfully piloting the prototype version of RITHMI technology, the team can confirm the capability of its breakthrough product to open new markets in Europe with the potential for rapid growth. Rithmi is a pioneer in arrhythmia detection technologies and the leading company in Computational Predictive Care™.

LuxAI is an innovative startup specialized in disruptive robotic solutions for education, health-care and entertainment. LuxAI is spin-off of the University of Luxembourg specialized in socially Assistive Robotics. LuxAI uses the latest advancements in Artificial Intelligence and robot-therapy in building social robots to assist people. Their mission is to make socially assistive robots economical and user-friendly in order to enable all teachers, therapists and care givers to use advanced robots in their everyday work of improving the health and education of people.

Mirrakoi SA is a Swiss company established in 2018 and is a spin-off from the Swiss Federal Institute of Technology in Lausanne. It specializes in developing computer-aided design software, particularly focused on the medical field. The company's flagship product, Rhino3DMedical, facilitates a seamless workflow that allows users to view, analyze, and segment medical images, ultimately enabling the creation of 3D-printable meshes and CAD models from CT and MRI scans. This proprietary software is designed with a user-friendly interface, making it accessible for orthopedic surgical planning and the production of patient-specific anatomical models. Mirrakoi's innovative technology streamlines the process of generating anatomical 3D prints, enhancing both efficiency and precision in medical applications.

DART Diagnostics was created with the purpose of improving diagnostics. As scientists, our founders, deal with detection problems on a daily basis. Although more alert to news in their own fields of research the need for better and earlier results is widely spread across water analysis, food safety, and of course clinical diagnostis.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016 and based in Barcelona, Spain, the company specializes in creating non-invasive tests for the in-situ diagnosis of various cancers using patients' blood. It also develops in-vivo diagnosis systems that assist in surgical procedures and monitor patient conditions, alongside therapeutical drugs aimed at treating cancer. Moirai Biodesign's innovative pipeline includes RNA biomarker discovery, the design of plug-and-play bio devices, and advanced platform delivery systems, all aimed at improving early cancer detection and targeted treatment options.

Ophiomics S.A. is a clinical-stage biotech company based in Lisbon, Portugal, specializing in the development of diagnostic products and services for liver cancer. Established in 2015, Ophiomics focuses on integrating bioinformatics, artificial intelligence, and genomics to enhance diagnostic and prognostic capabilities in oncology. The company is ISO 13485 and ISO 9001 certified, ensuring adherence to high-quality standards in its operations. Its product pipeline encompasses various stages of development, including pre-clinical programs and those undergoing clinical validation. Ophiomics aims to improve early detection of liver cancer through biomarker-based diagnostic devices that combine molecular signatures with clinical parameters in predictive algorithms, ultimately assisting healthcare providers in treatment selection and clinical follow-up for better patient outcomes.

Invent Medical's mission is helping people. New technology will constantly disrupt and change the medical field. They apply digital technologies to invent, develop and design a new generation of custom-made orthotic & prosthetic products so patients can experience better treatment outcomes.

LifeTag is a Portuguese technology startup that specializes in the research and development of non-invasive diagnostic technologies aimed at evaluating metabolism and diagnosing various high-incidence metabolic diseases, such as diabetes, obesity, and metabolic syndrome. The company has developed a diagnostic marker that facilitates non-invasive health monitoring, particularly focusing on intestinal permeability to enhance the accuracy of chronic metabolic disease diagnoses. By providing healthcare professionals with effective tools to assess patients without causing discomfort or side effects, LifeTag aims to improve health outcomes and streamline the diagnostic process.

Avia-GIS NV is a Belgian SME founded in 2001 that specializes in spatial risk mapping and modelling as a basis for the development of tailored spatial decision support systems applied to public-, animal- and crop health and integrated pest management. Their company has a unique market position. Only few companies operate in their domain and developed such close contacts with the industrial, institutional and academic world. They have offices in Belgium, South Africa and Guadeloupe, and are active in more than 50 countries.

AXO Science is dedicated to enhancing public health through the development of innovative diagnostic solutions. The company has created a forensic testing tool that offers multi-parameter diagnostic characterizations. This sophisticated tool features an integrated biochip, which incorporates multiple oligonucleotide probes grafted onto a polymer membrane. As a result, forensic departments and diagnostic enterprises can utilize advanced technologies for molecular-based diagnosis, improving their capabilities in the field of diagnostics.

Symptoma facilitates a search engine that enables physicians to search and find information related to diseases according to its symptoms. It enables them to find further symptoms, lab results, diagnostic test results, and complications related to diseases. Symptoma enables physicians to search information according to their patients’ symptoms, age, location, and gender. Symptoma was founded by Jama Nateqi and Thomas Lutz in 2009. It is based in Salzburg, Austria.

Biomode is a Portuguese startup located in Caldas das Taipas that specializes in developing rapid and accurate molecular diagnostic tests for identifying pathogens within the food, environmental, and life sciences sectors. Utilizing Peptide Nucleic Acid Fluorescence In Situ Hybridization (PNA-FISH) technology, Biomode's diagnostic kits provide a streamlined approach that eliminates the need for DNA extraction or amplification, ensuring reliability in the presence of inhibitory compounds and focusing solely on viable bacterial cells. The company plans to launch its first product, Probe4Salmonella®, for detecting Salmonella in food samples, followed by additional kits for Listeria monocytogenes and E. coli O157:H7. In the clinical diagnostics realm, Biomode has developed Probe4Pylori®, which is designed for the rapid identification of clarithromycin-resistant Helicobacter pylori strains and is currently seeking investigational device exemption from the FDA to commence field trials. Founded by researchers from the universities of Minho and Porto, Biomode aims to enhance pathogen detection in both food safety and health diagnostics.

GenomSys is a Swiss health software company focused on advancing personalized genomics through its innovative platform. The company has developed a modular and certified solution that enhances the efficiency, sharing, and analysis of genomic data. By utilizing the ISO/IEC 23092 genomic standard, known as MPEG-G, GenomSys enables significant reductions in storage needs and accelerates the time-to-market for new applications. Its platform securely stores individual DNA data on personal devices, facilitating sharing with healthcare practitioners for diagnostics and personalized treatments. Additionally, GenomSys provides vertical genomic analysis applications and connects to a mobile marketplace, ensuring interoperability and accessibility of high-quality genomic analyses. These features aim to improve healthcare outcomes and enhance the quality of life for individuals through advanced genetic insights.

Macro Array Diagnostics is a Vienna-based MedTech company. They develop, produce and distribute tests, instruments and software for allergy diagnostics and research applications. Their products allow flexible, reliable and affordable sensitization profiling of each patient. Their multidisciplinary team ensures that customers receive the most advanced tools to fulfill their diagnostic needs.

Tethis is a developer of a smart diagnostic device designed to create a diversified range of potential applications in diagnostic, therapeutic, and drug discovery. It also provides tools to support personalized medicine and targeted therapy in clinical settings.

BluSense Diagnostics specializes in developing innovative blood testing devices aimed at diagnosing infectious diseases. The company's technology utilizes a nanotechnology biosensing method, allowing for accurate results from just a single drop of blood. This consumer-oriented device enables individuals to monitor and manage virus outbreaks effectively. By integrating advanced Scandinavian bioengineering with high-quality Taiwanese hardware and software engineering, BluSense has established a breakthrough diagnostics system that addresses the pressing need for efficient infectious disease testing.

Oncoscanner is an oncological probe for intra-operative identification of cancerous tissues during surgical treatment for breast cancer.

Glucostratus Ltd develops innovative solutions for remote monitoring of blood glucose levels, primarily targeting patients with diabetes and healthcare professionals. Founded in 2005 and based in Helsinki, Finland, the company provides a cloud-based platform that captures blood glucose data via mobile technology, enabling patients to share their results with healthcare providers. This system allows professionals to set personalized targets and receive automated alerts regarding any deviations, facilitating effective remote monitoring of insulin treatment. Additionally, Glucostratus offers a digital solution for diagnostic testing and generates comprehensive reports in accordance with treatment guidelines. Their services include a user-friendly IoT solution designed for elderly diabetics, ensuring accessibility for those with limited technological skills and addressing the growing needs of the home care sector.

Atana have offices throughout the United Kingdom, and respond to enquiries from the UK and Europe. Their head office based in Leicestershire, East Midlands, houses manufacturing, logistics, laboratory, engineering and administrative support departments. Their technical sales department is made up of experts from the fields of engineering, chemistry and manufacturing. Atana’s technical sales support, marketing, compliance and laboratory departments are all staffed by individuals experienced in quality and environmental management systems. NEBOSH qualified staff manage their health and safety department. They have a number of strategic alliances with key players from the wastewater treatment industry and can offer advice on effluent plant treatment design, plant servicing and optimization as well as operative training.

Lyme Diagnostics offers reliable, standard diagnostic system for diagnosing Lyme borreliosis. Lyme diagnostics is primarily focused on the more exact, routine diagnostics of Lyme disease, building on the innovative technologies developed by the diagnostic & therapeutic workgroup of the Lyme Borreliosis Foundation. We offer the results of 30 years of work by 8 medical professionals. Currently, our novel diagnostic methods are supplemented with laboratory-standard, widely-accepted diagnostic procedures, and carefully confirmed by clinical diagnosis. The company's objective is that - after clinical testing - we will be able to offer one single screening method across Europe, and in North America.

Mermaid Care is a medical Technology firm that provides leading technology, care systems and solutions in optimizing the Ventilation Management within the Intensive Care Unit and Anaesthesia segment. Founded in 2006, the company has envisioned to be globally recognized amongst Key Opinion Leaders and Commercial Partners.

PharmaBiome is specialized in the isolation, characterization, and technology of novel intestinal microbes. Their technology platform optimizes the lean and efficient development and production of defined, function-based microbiome therapies to treat intestinal diseases. PharmaBiome’s proprietary development pipeline allows a fast translation from the identification of mode of action to a product ready for clinics, using tailored, ecologically sound bacterial mixtures.

PixCell Medical Technologies develops, produces, and markets portable medical diagnostic products for point of care testing. PixCell's products are based on its innovative Viscoelastic Focusing (VEF) technology and single use cartridges that enable rapid, accurate and simple blood sampling and analysis. Results are displayed within minutes in an easily readable format. PixCell's mission is to make tests currently restricted to the laboratory more accessible, easy to use and affordable.

Serosep is a manufacturer and a distributor of laboratory diagnostic solutions. Serosep Limited is founded in Limerick Ireland. Serosep begins life as distributor of laboratory diagnostic products. The manufacture of HistoPot®, Biopsy Fixation Solutions for Histopathology begins. Precision water chemistry reagents are launched. Development of EnterBio® faecal/stool pathogen test kit for bacteria begins.

EyeControl is a pioneer in medical technology focused on innovative communication solutions for healthcare. The company has developed a unique device aimed at improving the quality of life for patients with locked-in syndrome, particularly those suffering from ALS. This device consists of a simple glass frame equipped with an infrared camera that connects to a compact computer. It translates the patients' blinks and eye movements into commands, which are then converted into speech through earphones and a speaker. By leveraging advanced technology, EyeControl addresses significant communication barriers, enabling patients to express their needs and preferences more effectively.

HAWK Biosystems specializes in cancer diagnostics through a companion diagnostics platform that identifies post-translational modifications and protein-protein interactions in pathology samples. The platform quantifies these interactions in single-cell and fixed tissue samples, maintaining the integrity and heterogeneity of the tissue. This technology offers medical practitioners and pharmaceutical companies a novel approach to treatment decisions, particularly in cancer, inflammation, and immune disorders. HAWK Biosystems aims to enhance precision medicine by enabling targeted therapies that match patients with the treatments most likely to be effective, thereby improving patient outcomes, quality of life, and reducing overall drug costs. The company seeks to establish collaborative opportunities within the European health system to further its impact in the field.

Amolab's mission is to provide the world medical community with the first technological solution for the safe, automatic and non-invasive monitoring of labor. Amolab offers doctors an objective and reliable tool to assess fetal well-being during the transition from intrauterine to extrauterine life. Amolab's vision is to put science at the service of society for the development of non-invasive solutions aimed at improving the quality of life and making the global health system more effective and more sustainable. The goal of the company is to be a leading company in the field of technological innovation applied to the medical-health field.

NeuroPsyCAD provides clinicians with patient-personalized reports for early and accurate diagnoses of neuropsychiatric disorders. NeuroPsyCAD's analysis pipeline is automated, with a report being produced in a few hours since they receive the patient's data. Given the high sensitivity and specificity of our approach, subtle changes in brain structure and function can be detected early and accurately at the disease onset, enabling clinicians to diagnose and, thus, treat patients earlier and with more confidence. NeuroPsyCAD aims to replace the so far relatively subjective and metrics-independent practice of psychiatry and neurology with a more quantified, objective, accurate, and personalize one.

Tremitas is the developer of Tremipen®, a measuring device for Parkinson and other tremor diseases. The Tremipen® is a medical device that can be used by tremor patients themselves to safely and reliably measure the strength and frequency of the tremor. The Tremipen® is as easy to use as a clinical thermometer. It gives patients the feeling of control and provides physicians with objectively secured values ​​that can support diagnosis and therapy selection.

Salumedia Labs is a developer of evidence-based digital therapeutics focused on enhancing adherence to healthy lifestyles and medical treatments. The company utilizes behavioral science, artificial intelligence, and digital engagement techniques to create products that empower patients and facilitate lifestyle changes. In 2021, Salumedia Labs was acquired by Adhera Health, Inc., furthering its mission to support individuals in their health journeys.

Glycobond specializes in the development and production of proprietary carbohydrate-binding reagents aimed at enhancing diagnostics for liver diseases and cancer. The company has created HepaCheC™, an ELISA-based assay that identifies abnormal and cancer-specific glycosylation on alpha-1 acid glycoprotein (AGP), an acute phase plasma protein primarily produced in the liver. This innovative assay allows for analysis using simple blood samples, leveraging a patented fucose-binding protein known as Mono-F. Glycobond's approach has demonstrated promising results in monitoring patients at risk of developing hepatocellular carcinoma (HCC), offering a valuable tool for physicians in diagnosing and managing liver conditions.

GeneFirst is a molecular diagnostics company working predominantly in the fields of infectious disease, cancer diagnostics and personalized medicine. GeneFirst offers robust easy-to-use, sensitive, and affordable molecular diagnostics technologies and products to researchers, clinicians, and drug companies to enable accurate diagnosis and the delivery of safe and effective medicines. Its patented technologies allow for simultaneous detection of multiple targets in one reaction.

Ar Diagnostic is a technology-based company dedicated to the analysis of levels of comfort and control of indoor air quality in buildings. Indoor environment must provide the adequate conditions for human comfort, free of public health risks or hazards and the conditions for productivity enhancement. In an ever demanding market economy, each sector as to respond to high standards of excellence and closely observe the emerging needs of the modern society. To invest in the analysis of comfort levels and indoor air quality, represents a valuable asset. This project was distinguished in 2004 with the “best business idea” award in the Ideas and Business Contest within Project FIVE promoted by IAPMEI with the support of the Portuguese Ministry of Economy.

PKVitality is a bio-wearable company based in Paris, France, that specializes in developing innovative health monitoring devices. Its flagship product, K'Watch Glucose, is a smartwatch-style continuous glucose monitoring device that employs a micro-needle sensor to allow diabetics to monitor their glucose levels painlessly and discreetly. This wearable tracker is designed to provide real-time data without the need for calibration, offering a complete history of glucose levels and sending alerts for potential hypo or hyperglycemia episodes. Additionally, PKVitality is expanding its product line to include a Continuous Lactate Monitor and multi-analyte continuous monitors, which will further enhance the capabilities of their health monitoring technology. Founded in 2017, PKVitality aims to simplify health management for individuals, particularly those with diabetes, by eliminating the discomfort associated with traditional blood tests.

MedicSen is a start-up dedicated to health care, to technological innovation as a key tool. With several projects under mind, we have launched the most ambitious of them all, GlycSen. It is designed for intelligent treatment of insulin dependent diabetes device.

IBEX Innovations Limited specializes in developing and commercializing advanced X-ray detector technology that provides high sensitivity materials information using standard X-ray systems. Founded in 2010 by Dr. Gary Gibson and based in Sedgefield, United Kingdom, the company has created the IBEX multi absorption plate (MAP) technology, which enhances traditional detectors by integrating materials information while maintaining key performance characteristics like speed and spatial resolution. IBEX's solutions are utilized across various sectors, including healthcare for bone mineral density assessment, electronics inspection, food safety, and security applications. The company collaborates with academic institutions, such as the Mathematics Department at Durham University, and maintains partnerships with healthcare organizations to validate its technology in medical imaging. Supported by venture capital and grants, IBEX Innovations continues to advance its technology to transform standard X-ray imaging into powerful diagnostic tools.

DOFREN engages in the production and sale of beds and chairs with progressive pressure self-massage mechanism.

Amadix is focused on developing and commercializing innovative cancer diagnostic technologies that address unmet medical needs in oncology. The company's flagship product, Colofast, is a non-invasive screening signature for colorectal cancer and advanced adenoma diagnosis, aimed at reducing the high mortality rate associated with colon cancer. Amadix's approach emphasizes early detection, allowing for timely treatment while avoiding the complications of invasive procedures like tumor biopsies. The team comprises industry veterans with extensive expertise in oncology diagnostics, the pharmaceutical industry, and biotechnology, supported by independent board members who provide strategic guidance in commercialization and business development, particularly in Europe and the United States. Amadix's products undergo rigorous analytical validation and clinical studies before being introduced to the global market.

Ontech Group is a leader in Controlled Electromagnetic Field (CEMF) sensing technology, which transforms the way humans interact with machines and technology. With a global presence that includes offices and research and development centers, Ontech specializes in near-field detection, providing innovative solutions across various industries such as health technology, automotive, and consumer devices. The company's proprietary CEMF sensors, protected by over 100 international patents, enhance safety and functionality while promoting energy efficiency. Ontech's technology is applicable in diverse areas, including home security and industrial safety, enabling clients to optimize the protection of individuals and assets in both domestic and industrial settings.

Eversens is a company focused on the design, development, and manufacturing of non-invasive clinical diagnostic systems that detect exhaled biomarkers. Its technology aims to facilitate the diagnosis and monitoring of various diseases, providing patients with reliable and painless diagnostic options. By enhancing the accuracy of exhaled biomarker detection, Eversens seeks to improve individuals' health and quality of life while promoting a sustainable healthcare system.

UgenTec, based in Hasselt, is a rapidly growing company that specializes in developing software for molecular diagnostics. The company offers an independent diagnostic platform that supports molecular laboratories in analyzing DNA through real-time PCR technology. UgenTec's software automates the interpretation of PCR assays, enabling lab technicians to significantly reduce analysis time from 1.5 hours to just 3 minutes without the need for extensive training. This advancement not only boosts laboratory efficiency but also enhances diagnostic reliability for patients. UgenTec's innovative approach has garnered multiple awards and recognitions, reflecting its commitment to improving laboratory workflows and outcomes in the field of molecular diagnostics.

Impress Medtech develops a technology for continuous blood pressure monitoring during surgery. Impress technology works with electrodes placed on the patient’s chest. Blood pressure values on a beat-to-beat basis result from impedance measurements of the thorax complemented with upper-arm cuff measurements for calibration. With Impress this feature will be available for a large variety of operations but also in geographical regions that still need to catch up in health care standards. The method requires virtually no training for medical personnel, has hardly any limitations and is unbeatable with respect to cost-efficiency. The company seeks to set an international standard from which users, patients, and the public health system as a whole may equally benefit due to better operation results, shorter convalescence, and lower costs.

SocialDiabetes is a digital health company focused on improving the management and treatment of type 1 and type 2 diabetes. By transitioning away from traditional paper logbooks and rigid protocols, SocialDiabetes offers innovative software solutions designed to enhance the daily lives of individuals with diabetes. Its primary offerings include a patient app and a web platform that facilitates efficient engagement between healthcare professionals and their patients. With diabetes affecting over 400 million people globally and representing a significant economic burden on healthcare systems, SocialDiabetes aims to empower patients with autonomy and actionable insights while enabling healthcare providers to monitor patients in real time. This technology-driven approach fosters a more interactive and personalized care experience, allowing patients to take an active role in their health management and helping professionals deliver high-quality care remotely.

Castor is an international health-tech company founded by CEO Derk Arts, MD, Ph.D. Their cloud-based clinical data platform simplifies the entire clinical trial process, from recruitment to analysis, for researchers worldwide. More than 50,000 researchers across 90 countries are using Castor to supercharge their research. Castor’s platform has supported more than 4,000 commercial and academic studies that cover a broad range of therapeutic areas including diabetes, cardiovascular disease, rare diseases, infectious diseases, and oncology. Researchers on the platform generate vast amounts of data from traditional and remote trials, and Castor recently reached milestones of 180,000,000 data points and 2,000,000 enrolled patients. Castor’s goal is to make the world’s research data reusable, enabling AI-driven clinical trials, and ultimately creating a future in which they maximize the impact of data through reuse.

Lab Service Analytica is a leader in pre and post sales assistance. It provides a wide range of essential analysis tools for research, development, and quality control. It also provides instruments for measurements of chemical-physical parameter that are essential to guaranteeing quality of life. Lab Service was created to meet the growing demand for special consumables used in chemical and pharmaceutical laboratories for research analysis and quality control. The company believes in the innovation and use of new technologies at high levels, an aspect in which it is active in the very first line. It has developed its own proprietary brands over time and focuses on the continuous technological progress of its service. Its goal is to constantly set new quality standards for its products and its support services for customers.

Kinetic Center of Modern Audiology is a network of advanced audiology centers dealing with effective treatment and diagnostics of tinnitus.

Infermedica is a digital health company focused on improving the accuracy of medical diagnoses and optimizing the use of healthcare services. It provides AI-powered preliminary diagnosis and triage solutions to insurance companies, hospitals, and health systems, addressing issues related to misdiagnosis and inappropriate service utilization. The company's platform assists users by analyzing symptoms and facilitating communication with clinical staff for further diagnostics. Infermedica's tools have been utilized by over 6 million users globally, and it collaborates with more than 50 organizations, including notable partners in the healthcare sector. The company emphasizes the reliability of its recommendations by having a team of physicians review the medical database, ensuring that the information provided is accurate and safe. With over 100 employees and products available in 17 languages, Infermedica aims to enhance healthcare accessibility and reduce costs. Recent funding of $10.25 million will support its expansion in the United States and Europe and further technological development.

OutSense develops an IoT medical device aimed at early illness detection and wellness monitoring through the analysis of human waste. Utilizing innovative imaging technologies, the device detects tiny quantities of blood mixed with stool directly within a standard toilet bowl. This capability allows for the generation of daily medical status reports for individuals, alerting caregivers to health deviations and potential abnormalities. The primary focus of OutSense is the prevention of colorectal cancer by identifying hidden blood in stool, a well-established screening method that traditionally requires sending samples to specialized laboratories. By integrating this technology with a mobile application, OutSense aims to enhance proactive health management and improve early diagnosis.

Nano4 provides solutions for rapid colorimetric identification of molecular targets of disease (DNA/RNA) at point-of-care (PoC). NANO4 Global is a startup launched in 2015 to market nanotechnology based molecular diagnostics. The NANO4 is a nanodiagnostics platform that provides simple colorimetric detection of DNA and RNA with single base selectivity. Following more than 12 years of research in nanodiagnostics at Universidade NOVA de Lisboa - Science and Technology, Department of Lifesciences, this technology was awarded the Scientific Prize - Santander Totta / Universidade NOVA de Lisboa.

Mycometer develops methods of documentation and delineation of microbial contamination in buildings and Water systems. Mycometer technology is being used across 5 continents and improves the quality of life for millions of people around the globe every day. All Mycometer products are patented and trademarked by Mycometer. The technology has been tested and verified by US-EPA (2011). Reproducibility was found to be very good with a relative standard deviation on the mean between 1.4 and 8.7 % when different assays and conditions were used. The calculation includes both variability on sampling, analysis, analyst and instrumentation. Mycometer technology has been a DOD preffered technology with the US Department of Defence since 2010. Mycometer technology is also used for verification of Water Hygiene in Professional Quality Systems ISO 22000/HACCP. Mycometer technology is documented in peer-reviewed scientific publications and we enjoy close collaborations with the industrial, consulting as well as scientific communities.

MediSieve Ltd. is a medical device company based in London, United Kingdom, focused on developing Magnetic Blood Filtration (MBF) technology to treat blood-borne diseases. Established in 2014, the company has created a blood filtration device that magnetically removes infected blood cells, enabling the treatment of conditions such as malaria, leukemia, and sepsis. The MBF system operates by circulating a patient’s blood through an external loop where targeted magnetic particles bind to disease-relevant targets. The blood then passes through a magnetic filter that captures these particles and bound targets, allowing the unaffected blood to be returned to the patient. MediSieve's innovative approach also aims to enhance the safety and efficacy of existing therapies while expanding the range of treatable diseases. The company operates from the Imperial Incubator in White City, London, where it has specialized laboratory facilities for product development and validation.

SiriusXT Limited, based in Dublin, Ireland, specializes in the development and manufacturing of a soft x-ray microscope known as the SXT system. Founded in 2015, the company primarily serves researchers in disease research and drug discovery. The microscope employs a vacuum-based laser-produced plasma light source, enabling high-resolution imaging of the 3D internal structure of cells in their native, fully hydrated state. This technology is akin to a CT scan for cells, allowing for detailed visualization without the need for stains or contrast agents. The SXT system is particularly beneficial for disease researchers, pharmaceutical companies, and biotechnologists, as it facilitates the understanding of disease pathways, protein-drug interactions, and bio-engineering processes. As the first high-throughput, bench-top soft x-ray microscope, SiriusXT's system can produce full cell 3D tomographs in a matter of minutes, significantly advancing imaging capabilities in scientific research.

GlycoMar Limited is a biotechnology company focused on discovering and developing innovative products for the human healthcare and personal care markets. Founded in 2005 and based in Oban, United Kingdom, GlycoMar specializes in addressing unmet clinical needs related to inflammatory diseases such as eczema, psoriasis, asthma, and inflammatory bowel disease through the development of consumer healthcare products and novel pharmaceuticals. The company also creates glycomolecule products for the cosmetic and nutraceutical sectors. In addition to product development, GlycoMar offers a comprehensive range of carbohydrate research and development services, from initial discovery to pilot-scale processing. The company collaborates with MicroA AS in a joint venture to manufacture cosmetic ingredient products. GlycoMar's efforts are rooted in the exploration of marine organisms, enabling it to evaluate and commercialize unique biological products that serve the pharmaceutical, consumer healthcare, cosmetic, and nutraceutical markets.

New Gluten World (NGW) is a company set up by the University of Foggia, Molino Casillo SpA, a world leader in the transformation of grain, and the lead researcher Carmen Lamacchia. It aims to globally promote a gluten-friendly methodology that will displace current gluten free approaches to the celiac disease in preparation of cereal-based foodstuff. The methodology is patent protected in 105 countries worldwide. NGW’s mission is to break down the nutritional divide, that discriminates celiac patients (who are intolerant and sensitive to gluten) against healthy individuals. Enabling milling companies and producers worldwide to detoxify gluten through the proprietary methodology will progressively overcome the traditional gluten free products and make all individuals part of the gluten friendly revolution.

Salumedia Labs is a developer of evidence-based digital therapeutics focused on enhancing adherence to healthy lifestyles and medical treatments. The company utilizes behavioral science, artificial intelligence, and digital engagement techniques to create products that empower patients and facilitate lifestyle changes. In 2021, Salumedia Labs was acquired by Adhera Health, Inc., furthering its mission to support individuals in their health journeys.

Microptic is a company based in Barcelona, Spain, that specializes in the research, development, distribution, and installation of automatic diagnostic systems. The firm focuses on software development for image analysis and provides in-vitro diagnostic systems. By leveraging artificial intelligence, Microptic enables clients to use robotic systems that automate microscopic analysis, enhancing the efficiency and accuracy of diagnostic processes. The company's comprehensive offerings include research, design, development, sales, installation, and service, positioning it as a key player in the field of diagnostic technology.

Grademi Biotech is developing a patented device, X10 Pathology to enhance the diagnostic value of ESR testing. The erythrocyte sedimentation rate (ESR) is a widely used non-specific blood test for inflammation, used to help support the diagnosis of a wide range of diseases and monitor therapy. X10 Pathology correlates ESR rate in plasma to specific disease states creating new functionality and dramatically improved performance. This allows: more rapid and specific disease diagnosis; reduced need for additional diagnostic testing and improve disease monitoring. The X10 Pathology is undergoing validation testing at a leading hospital in Italy.

Lifecare AS is a privately owned company based in Bergen, Norway, dedicated to the research and development of medical sensors for health monitoring since its founding in 2006. The company primarily focuses on developing tools for monitoring glucose levels, marketed under the name SENCELL. Lifecare AS conducts its research and development activities in collaboration with European affiliates and is financed through private investors and governmental grants.

Dianax, founded in 2013 in Milan by a team of scientists led by Eugenio Iannone and Maurizio Moroni, focuses on developing and manufacturing lab-on-chip technologies for protein-based diagnostics. The company's innovative approach combines microfluidic innovations with electrochemical detection systems, enabling the creation of portable diagnostic devices that can analyze blood and other body fluids. Dianax's technology aims to provide accurate, reliable, and affordable diagnostic results, making them easily accessible to both patients and healthcare professionals. By empowering users with prompt and effective diagnostic tools, Dianax supports improved prevention, management, and emergency treatment in clinical settings.

Ar Diagnostic is a technology-based company dedicated to the analysis of levels of comfort and control of indoor air quality in buildings. Indoor environment must provide the adequate conditions for human comfort, free of public health risks or hazards and the conditions for productivity enhancement. In an ever demanding market economy, each sector as to respond to high standards of excellence and closely observe the emerging needs of the modern society. To invest in the analysis of comfort levels and indoor air quality, represents a valuable asset. This project was distinguished in 2004 with the “best business idea” award in the Ideas and Business Contest within Project FIVE promoted by IAPMEI with the support of the Portuguese Ministry of Economy.

Saccade Diagnostics brings to market for the first time clinically-validated objective tests to help clinicians with diagnostic evaluation and management of psychiatric disorders in patients with mental health complaints. A spin-out from the University of Aberdeen, Saccade has devised a rapid eye-movement test called SaccScan that can help medical professionals diagnose a range of psychiatric disorders, such as schizophrenia, bipolar disorder and major depression within just 30 minutes. It is non-invasive, affordable and easy to administer, allowing non-specialists to operate it with minimal training. The academic founders, Philip Benson and David St Clair, teamed up with Madhu Nair, who took on the role of commercial champion and CEO.

Liopa Ltd is a Belfast-based company that specializes in biometric authentication and verification technology. Established in 2015, it has developed LipVerify, a solution that validates user identity by analyzing lip movements as they speak into a camera. Drawing from over 15 years of PhD research in speech and image processing, Liopa has created an automated lipreading technology rooted in machine learning and artificial intelligence. The company is notable for introducing commercially available visual speech recognition technology, with its primary application being SRAVI. This smartphone app is designed to assist individuals who have lost their ability to speak, enabling them to communicate by deciphering their lip movements. SRAVI is currently undergoing trials in Intensive Care units within the NHS, providing a crucial communication tool for patients and their caregivers.

Kleinklein researches chronic pain and provides real solutions, therapies, courses, and workshops to help people understand their pain. We help them and their spouses take steps that reduce the frequency and severity of pain. Kleinklein knows that chronic pain can be debilitating. Although often unrelated to a medical condition, the pain is perceived, real, persistent, and can be seen in the MRI. Pain can be visceral or somatic, nociceptive or neuropathic, and deeply affects lives.

mySkin, Inc. is a skincare technology company founded in 2007 and based in Jersey City, New Jersey. The company develops innovative skin care devices and products, including the OKU anti-aging device and app, as well as the dermograph, a transdermal skin consultation system that utilizes proprietary imaging technology to assess skin health. mySkin also hosts a comprehensive online platform that offers over one million skincare products and employs a unique algorithm to provide personalized product recommendations based on users' skin profiles, which consider factors such as genetics, diet, and lifestyle. The platform fosters a collaborative community where individuals can share their experiences and insights about various skincare products. Additionally, mySkin has developed mobile applications, including a top skincare app for iPhone and a Windows app called SkinScan, which aids in detecting early signs of melanoma. Through its innovative approaches, mySkin aims to empower individuals to better understand their skin and connect with suitable products for their skincare needs.